Cytochrome P450 enzymes: novel options for cancer therapeutics

Morag Catherine Elliott McFadyen, William Thomas Melvin, Graeme Ian Murray

Research output: Contribution to journalEditorial

160 Citations (Scopus)

Abstract

The concept of overexpression of individual forms of cytochrome P450 enzymes in tumor cells is now becoming well recognized. Indeed, a growing body of research highlights the overexpression of P450s, particularly CYP1B1, in tumor cells as representing novel targets for anticancer therapy. The purpose of this review is to outline the novel therapeutic options and opportunities arising from both enhanced endogenous expression of cytochrome P450 in tumors and cytochrome P450-mediated gene therapy.

Original languageEnglish
Pages (from-to)363-371
Number of pages8
JournalMolecular Cancer Therapeutics
Volume3
Issue number3
Publication statusPublished - 2004

Keywords

  • INDOLE ALKALOID BIOSYNTHESIS
  • BREAST-CANCER
  • IN-VITRO
  • ANTICANCER AGENT
  • PRIMARY CULTURES
  • DRUG-METABOLISM
  • RETINOIC ACID
  • GENE-THERAPY
  • CELL-LINES
  • TAXOL BIOSYNTHESIS

Cite this

Cytochrome P450 enzymes: novel options for cancer therapeutics. / McFadyen, Morag Catherine Elliott; Melvin, William Thomas; Murray, Graeme Ian.

In: Molecular Cancer Therapeutics, Vol. 3, No. 3, 2004, p. 363-371.

Research output: Contribution to journalEditorial

McFadyen, Morag Catherine Elliott ; Melvin, William Thomas ; Murray, Graeme Ian. / Cytochrome P450 enzymes: novel options for cancer therapeutics. In: Molecular Cancer Therapeutics. 2004 ; Vol. 3, No. 3. pp. 363-371.
@article{7826705f1fd74f5da093cb71a31aa11a,
title = "Cytochrome P450 enzymes: novel options for cancer therapeutics",
abstract = "The concept of overexpression of individual forms of cytochrome P450 enzymes in tumor cells is now becoming well recognized. Indeed, a growing body of research highlights the overexpression of P450s, particularly CYP1B1, in tumor cells as representing novel targets for anticancer therapy. The purpose of this review is to outline the novel therapeutic options and opportunities arising from both enhanced endogenous expression of cytochrome P450 in tumors and cytochrome P450-mediated gene therapy.",
keywords = "INDOLE ALKALOID BIOSYNTHESIS, BREAST-CANCER, IN-VITRO, ANTICANCER AGENT, PRIMARY CULTURES, DRUG-METABOLISM, RETINOIC ACID, GENE-THERAPY, CELL-LINES, TAXOL BIOSYNTHESIS",
author = "McFadyen, {Morag Catherine Elliott} and Melvin, {William Thomas} and Murray, {Graeme Ian}",
year = "2004",
language = "English",
volume = "3",
pages = "363--371",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Cytochrome P450 enzymes: novel options for cancer therapeutics

AU - McFadyen, Morag Catherine Elliott

AU - Melvin, William Thomas

AU - Murray, Graeme Ian

PY - 2004

Y1 - 2004

N2 - The concept of overexpression of individual forms of cytochrome P450 enzymes in tumor cells is now becoming well recognized. Indeed, a growing body of research highlights the overexpression of P450s, particularly CYP1B1, in tumor cells as representing novel targets for anticancer therapy. The purpose of this review is to outline the novel therapeutic options and opportunities arising from both enhanced endogenous expression of cytochrome P450 in tumors and cytochrome P450-mediated gene therapy.

AB - The concept of overexpression of individual forms of cytochrome P450 enzymes in tumor cells is now becoming well recognized. Indeed, a growing body of research highlights the overexpression of P450s, particularly CYP1B1, in tumor cells as representing novel targets for anticancer therapy. The purpose of this review is to outline the novel therapeutic options and opportunities arising from both enhanced endogenous expression of cytochrome P450 in tumors and cytochrome P450-mediated gene therapy.

KW - INDOLE ALKALOID BIOSYNTHESIS

KW - BREAST-CANCER

KW - IN-VITRO

KW - ANTICANCER AGENT

KW - PRIMARY CULTURES

KW - DRUG-METABOLISM

KW - RETINOIC ACID

KW - GENE-THERAPY

KW - CELL-LINES

KW - TAXOL BIOSYNTHESIS

M3 - Editorial

VL - 3

SP - 363

EP - 371

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -